Stock Events

Stock Events

89bio 

$14.84
24
+$0+0% Wednesday 20:00

Statistics

Day High
14.87
Day Low
14.82
52W High
15.06
52W Low
4.16
Volume
39,232,756
Avg. Volume
5,898,267
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

6NovExpected
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
-1.39
-1.08
-0.77
-0.46
Expected EPS
-0.50625
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-367.08MNet Income

Analyst Ratings

$0.00Average Price Target
The highest estimate is 0.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ETNB. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Viking Therapeutics
VKTX
Mkt Cap4.3B
Viking Therapeutics is developing therapies for metabolic and endocrine disorders, directly competing with 89bio's focus on NASH and liver diseases.
Madrigal Pharmaceuticals
MDGL
Mkt Cap9.34B
Madrigal Pharmaceuticals focuses on the development of treatments for cardiovascular, metabolic, and liver diseases, including NASH, directly competing with 89bio's pipeline.
Galmed Pharmaceuticals
GLMD
Mkt Cap7.51M
Galmed Pharmaceuticals is involved in the development of oral therapies for the treatment of liver diseases like NASH, competing with 89bio's approach.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a broad portfolio including treatments for liver diseases, directly competing with 89bio in the NASH and liver disease space.
Agios Pharmaceuticals
AGIO
Mkt Cap2.52B
Agios Pharmaceuticals focuses on cellular metabolism and rare diseases, including metabolic and liver disorders, competing with 89bio's therapeutic areas.

About

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Show more...
CEO
Mr. Rohan Palekar
Employees
93
Country
US
ISIN
US2825591033

Listings

0 Comments

Share your thoughts

FAQ

What is 89bio stock price today?▼
The current price of ETNB is $14.84 USD — it has increased by +0% in the past 24 hours. Watch 89bio stock price performance more closely on the chart.
What is 89bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange 89bio stocks are traded under the ticker ETNB.
Is 89bio stock price growing?▼
ETNB stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year 89bio has showed a +157.19% increase.
What is 89bio revenue for the last year?▼
89bio revenue for the last year amounts to 0 USD.
What is 89bio net income for the last year?▼
ETNB net income for the last year is -367.08M USD.
How many employees does 89bio have?▼
As of April 04, 2026, the company has 93 employees.
In which sector is 89bio located?▼
89bio operates in the Health Care sector.
When did 89bio complete a stock split?▼
89bio has not had any recent stock splits.
Where is 89bio headquartered?▼
89bio is headquartered in San Francisco, US.